Kolexia
Tchiknavorian Xavier Oncologie médicale
Tchiknavorian Xavier
Oncologie médicale
Centre Hospitalier Toulon
Toulon, France
40 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du pancréas Carcinome épidermoïde Tumeurs du sein triple-négatives Tumeurs de la prostate Carcinomes Tumeurs de la tête et du cou Tumeurs du sein Métastase tumorale Tumeurs du poumon

Collaborateurs

Voir plus
Duberge Thomas
Duberge Thomas
Cds Medical, Toulon, France
Khoury Cedric
Khoury Cedric
Cds Medical, Toulon, France
Zioueche-Mottet Amira
Zioueche-Mottet Amira
Cds Medical, Toulon, France
Guerder Caroline
Guerder Caroline
Cds Medical, Toulon, France

Industries

Voir plus
MSD
9 collaboration(s)
Dernière en 2023
Lilly
6 collaboration(s)
Dernière en 2023
Bayer
5 collaboration(s)
Dernière en 2023
AstraZeneca
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION): A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Essai Clinique (Emd Serono)   05 mars 2024
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable): A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
Essai Clinique (Bayer)   10 mai 2023
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial.
Nature medicine   18 janvier 2021
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Annals of oncology : official journal of the European Society for Medical Oncology   05 juillet 2012
BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.
2011 ASCO Annual Meeting I   20 mai 2011
{{person.lastact6.name}}
{{person.lastact6.jour}}   {{person.lastact6.date}}
{{person.lastact7.name}}
{{person.lastact7.jour}}   {{person.lastact7.date}}
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}